919 results on '"Nikpour, M."'
Search Results
2. Aromatherapy with Rosa damascena Mill. to Relieve the Symptoms of Postpartum Depression and Sleep Quality in Primiparous Women: A Randomised Controlled Trial
- Author
-
Hosseini, F.Z., Behmanesh, F., Mirabi, P., Memariani, Z., Nikpour, M., Omidvar, Sh., Mozaffarpur, S.A., Sefidchian, A.R., and Aghamohammadi, A.
- Published
- 2024
- Full Text
- View/download PDF
3. Coupled data pre-processing approach with data intelligence models for monthly precipitation forecasting
- Author
-
Nikpour, M. R., Abdollahi, S., Sanikhani, H., Raeisi, J., and Yaseen, Z. M.
- Published
- 2022
- Full Text
- View/download PDF
4. AB1553-HPR BASELINE CHARACTERISTICS OF PATIENTS WITH SLE ACROSS 5 REGISTRIES – THE LUPUSNET FEDERATED DATA NETWORK
- Author
-
Sbarigia, U., primary, Zazzetti, F., additional, Lewi, M., additional, Van Speybroeck, M., additional, Simon, T. A., additional, Li, G., additional, Sonmez, R., additional, Carter, C., additional, Karyekar, C. S., additional, Noel, W., additional, Ugarte-Gil, M. F., additional, Gamboa-Cardenas, R. V., additional, Pons-Estel, G., additional, Borba, E. F., additional, Massardo, L., additional, Aroca Martínez, G., additional, Muñoz Louis, R., additional, Moreno Alvarez, M., additional, García De La Torre, I., additional, Acosta Colmán, I., additional, Mora Trujillo, C., additional, Danza, Á., additional, Michaud, K., additional, Katz, P., additional, Kandane-Rathnayake, R., additional, Morand, E., additional, Louthrenoo, W., additional, Chen, Y. H., additional, Cho, J., additional, Hamijoyo, L., additional, Luo, S. F., additional, Jan Wu, Y. J., additional, Navarra, S., additional, LI, Z., additional, Sockalingam, S., additional, Harigai, M., additional, Zhang, Z., additional, Basnayake, D., additional, Chan, M., additional, Takeuchi, T., additional, Bae, S. C., additional, Goldblatt, F., additional, ’neill, S. O, additional, Ng, K. P. L., additional, Tugnet, N., additional, Kumar, S., additional, Tee, M., additional, Tanaka, Y., additional, Lau, C. S., additional, Hoi, A., additional, Nikpour, M., additional, Rúa-Figueroa, Í., additional, Pego-Reigosa, J. M., additional, Galindo-Izquierdo, M., additional, Calvo Alén, J., additional, Fernández-Nebro, A., additional, Menor-Almagro, R., additional, and Lavie, F., additional
- Published
- 2024
- Full Text
- View/download PDF
5. OP0133 INVESTIGATING THE GENETIC BACKGROUND OF THE SEX DIMORPHISM IN SYSTEMIC SCLEROSIS
- Author
-
Rodriguez-Martin, I., primary, Kerick, M., additional, Rosa-Baez, C., additional, Borrego-Yaniz, G., additional, Ortiz-Fernández, L., additional, Guillen-Del-Castillo, A., additional, Simeón-Aznar, C. P., additional, Callejas, J. L., additional, Assassi, S., additional, Ssc Group, I., additional, Proudman, S. M., additional, Nikpour, M., additional, Interest Group (Asig), A. S., additional, Hunzelmann, N., additional, Moroncini, G., additional, De Vries-Bouwstra, J. K., additional, Orozco, G., additional, Barton, A., additional, Herrick, A. L., additional, Allanore, Y., additional, Fonseca, C., additional, Beretta, L., additional, Denton, C. P., additional, Mayes, M. D., additional, Martin, J., additional, and Acosta-Herrera, M., additional
- Published
- 2024
- Full Text
- View/download PDF
6. POS0152 PREVALENCE AND OUTCOMES OF SEVERE REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): OBSERVATIONS FROM A MULTINATIONAL COHORT
- Author
-
Kandane-Rathnayake, R., primary, Louthrenoo, W., additional, Lau, C. S., additional, Hamijoyo, L., additional, Cho, J., additional, Lateef, A., additional, Luo, S. F., additional, Jan Wu, Y. J., additional, Navarra, S., additional, Zamora, L., additional, LI, Z., additional, Chen, Y. H., additional, Oon, S., additional, Chan, M., additional, Sockalingam, S., additional, Hao, Y., additional, Zhang, Z., additional, Bae, S. C., additional, Kikuchi, J., additional, Takeuchi, T., additional, Katsumata, Y., additional, Harigai, M., additional, Basnayake, D., additional, Goldblatt, F., additional, ’neill, S. O, additional, Ng, K. P. L., additional, Tugnet, N., additional, Kumar, S., additional, Law Hui Nee, A., additional, Tee, C., additional, Tee, M., additional, Ohkubo, N., additional, Jullion, A., additional, Shisha, T., additional, Tanaka, Y., additional, Golder, V., additional, Nikpour, M., additional, Hoi, A., additional, and Morand, E., additional
- Published
- 2024
- Full Text
- View/download PDF
7. POS0549 OUTCOMES OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH INTRAVENOUS OR SUBCUTANEOUS BELIMUMAB: A POST-HOC EFFICACY META-ANALYSIS BY BICLA CRITERIA
- Author
-
Parodis, I., primary, Lindblom, J., additional, Çetrez, N., additional, Palazzo, L., additional, Oon, S., additional, Ala, H., additional, Van Vollenhoven, R. F., additional, Morand, E., additional, Levitsky, A., additional, and Nikpour, M., additional
- Published
- 2024
- Full Text
- View/download PDF
8. POS1132 POOR HEALTH-RELATED QUALITY OF LIFE DESPITE LOW DISEASE ACTIVITY OR REMISSION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
- Author
-
Parodis, I., primary, Lindblom, J., additional, Çetrez, N., additional, Palazzo, L., additional, Ala, H., additional, Nikpour, M., additional, Levitsky, A., additional, and Strand, V., additional
- Published
- 2024
- Full Text
- View/download PDF
9. Effect of Window Area and Proportions of Iwan on Daylight in Adjacent Room: An Investigation in Yazd City
- Author
-
Kamyab, A., primary, Mahmoudi Zarandi, M., additional, and Nikpour, M., additional
- Published
- 2024
- Full Text
- View/download PDF
10. Evaluation of Quality of Daylight in a Contemporary Residential Building with a Central Courtyard in Kerman, Iran
- Author
-
Movehhedi Nia, M., primary, Nikpour, M., additional, and Jahanshahi Javaran, E., additional
- Published
- 2024
- Full Text
- View/download PDF
11. Risk Assessment for Breast Cancer Development and Its Clinical Impact on Screening Performance in Iranian Women
- Author
-
Nikpour M, Hajian-Tilaki K, and Bakhtiari A
- Subjects
breast cancer risk ,the gail model ,the health belief model ,perceived risk ,the estimated risk ,screening behaviors. ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Maryam Nikpour,1 Karimollah Hajian-Tilaki,2 Afsaneh Bakhtiari3 1Student Research Committee, Health Research Institute, Babol University of Medical Sciences, Babol, Iran; 2Department of Biostatistics and Epidemiology, School of Medicine, Babol University of Medical Sciences, Babol, Iran; 3Department of Midwifery, School of Medicine, Babol University of Medical Sciences, Babol, IranCorrespondence: Karimollah Hajian-TilakiDepartment of Biostatistics and Epidemiology, School of Medicine, Babol University of Medical Sciences, Babol, IranEmail drhajian@yahoo.comIntroduction: The aim of this study is to estimate the objective and subjective risk and to examine their associations with three forms of breast cancer screening.Methods: This cross-sectional study was conducted with a sample of 800 women aged 35–85 years from the community setting and outpatient clinic in Babol, the north of Iran. The demographic, socio-economic characteristics and the risk factor profiles were collected through in-person interview. The health belief model (HBM) and visual analog scales were used to assess the women’s perceived risk of breast cancer. The practice of women regarding breast self-examination (BSE), breast clinical examination (BCE), and mammography were measured. We used the Gail model in estimating 5-year and lifetime risk. The logistic regression model was applied to determine the relationship of calculated and perceived risk on screening behaviors.Results: The mean of estimated 5-year and lifetime risk were 0.89 ±0.89 and 8.87 ±3.84 percent respectively while the perceived personal risk on visual scale perception was much greater than the calculated risk. The high 5-year calculated risk was a predictor of mammography practice but not BSE and BCE; however, after adjusting the subscales of HBM and socio-demographic characteristics, its effect remained significant (adjusted OR=1.97(95% CI: 1.02–3.08)). The perceived risk from HBM in particular self-efficacy (p=0.001) remained positively significant on all forms of screening practice.Conclusion: While the perceived risk from HBM scale was meaningful in screening performance, the calculated risk from the Gail model had a clinical impact on mammography behaviors independent of HBM scales.Keywords: breast cancer risk, the Gail model, the health belief model, perceived risk, the estimated risk, screening behaviors
- Published
- 2019
12. NT-proBNP is Associated With Both Pulmonary Hypertension and Diastolic Dysfunction in Patients With Systemic Sclerosis: An Australian Prospective Cross-Sectional Study
- Author
-
Ha, F., primary, Brown, Z., additional, Stevens, W., additional, Prior, D., additional, Ross, L., additional, Ferdowsi, N., additional, Nikpour, M., additional, and Burns, A., additional
- Published
- 2023
- Full Text
- View/download PDF
13. POS1269 INVESTIGATING THE TRAJECTORY OF FUNCTIONAL DISABILITY IN SYSTEMIC SCLEROSIS: GROUP BASED TRAJECTORY MODELLING OF THE HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX
- Author
-
Fairley, J., primary, Hansen, D., additional, Baron, M., additional, Proudman, S., additional, Sahhar, J. A., additional, Ngian, G. S., additional, Walker, J., additional, Host, L., additional, Morrisroe, K., additional, Stevens, W., additional, Ross, L., additional, and Nikpour, M., additional
- Published
- 2023
- Full Text
- View/download PDF
14. OP0235 DEVELOPMENT AND PRELIMINARY VALIDATION OF THE NOVEL SCLERODERMA CLINICAL TRIALS CONSORTIUM ACTIVITY INDEX
- Author
-
Ross, L., primary, Hansen, D., additional, Proudman, S., additional, Khanna, D., additional, Herrick, A., additional, Stevens, W., additional, Baron, M., additional, and Nikpour, M., additional
- Published
- 2023
- Full Text
- View/download PDF
15. AB0902 LEFT VENTRICULAR SYSTOLIC DYSFUNCTION IS RARE BUT PROGNOSTICALLY IMPORTANT IN SYSTEMIC SCLEROSIS
- Author
-
Fairley, J., primary, Hansen, D., additional, Proudman, S., additional, Sahhar, J. A., additional, Ngian, G. S., additional, Walker, J., additional, Host, L., additional, La Gerche, A., additional, Prior, D., additional, Morrisroe, K., additional, Stevens, W., additional, Nikpour, M., additional, and Ross, L., additional
- Published
- 2023
- Full Text
- View/download PDF
16. POS1481 INFORMING TRIAL MEASUREMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS: FREQUENCY OF DOMAIN-SPECIFIC DISEASE ACTIVITY IN A MULTI-NATIONAL OBSERVATIONAL COHORT
- Author
-
Connelly, K., primary, Kandane-Rathnayake, R., additional, Golder, V., additional, Louthrenoo, W., additional, Chen, Y. H., additional, Cho, J., additional, Lateef, A., additional, Hamijoyo, L., additional, Luo, S. F., additional, Jan Wu, Y. J., additional, Navarra, S., additional, Zamora, L., additional, LI, Z., additional, Sockalingam, S., additional, Katsumata, Y., additional, Harigai, M., additional, Hao, Y., additional, Zhang, Z., additional, Chan, M., additional, Kikuchi, J., additional, Takeuchi, T., additional, Oon, S., additional, Bae, S. C., additional, Goldblatt, F., additional, O’neill, S., additional, Ng, K., additional, Law, A., additional, Basnayake, B., additional, Tugnet, N., additional, Kumar, S., additional, Tee, C., additional, Tee, M., additional, Tanaka, Y., additional, Lau, C. S., additional, Nikpour, M., additional, Hoi, A., additional, and Morand, E. F., additional
- Published
- 2023
- Full Text
- View/download PDF
17. OP0048 RISK OF FLARE AND DAMAGE ACCRUAL AFTER TAPERING GLUCOCORTICOIDS IN SEROLOGICALLY ACTIVE CLINICALLY QUIESCENT PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
- Author
-
Katsumata, Y., primary, Inoue, E., additional, Harigai, M., additional, Kandane-Rathnayake, R., additional, Louthrenoo, W., additional, Hoi, A., additional, Golder, V., additional, Lau, C. S., additional, Cho, J., additional, Lateef, A., additional, Chen, Y. H., additional, Luo, S. F., additional, Jan Wu, Y. J., additional, Hamijoyo, L., additional, Li, Z., additional, Sockalingam, S., additional, Navarra, S., additional, Zamora, L., additional, Hao, Y., additional, Zhang, Z., additional, Chan, M., additional, Oon, S., additional, Ng, K., additional, Kikuchi, J., additional, Takeuchi, T., additional, Goldblatt, F., additional, O’neill, S., additional, Tugnet, N., additional, Law, A., additional, Bae, S. C., additional, Tanaka, Y., additional, Ohkubo, N., additional, Kumar, S., additional, Nikpour, M., additional, and Morand, E. F., additional
- Published
- 2023
- Full Text
- View/download PDF
18. OP0226 ATTAINMENT OF LUPUS LOW DISEASE ACTIVITY STATE EXCLUSIVE OF REMISSION IS PROTECTIVE AGAINST ADVERSE OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS
- Author
-
Kandane-Rathnayake, R., primary, Golder, V., additional, Louthrenoo, W., additional, Chen, Y. H., additional, Cho, J., additional, Lateef, A., additional, Hamijoyo, L., additional, Luo, S. F., additional, Jan Wu, Y. J., additional, Navarra, S., additional, Zamora, L., additional, LI, Z., additional, Sockalingam, S., additional, Katsumata, Y., additional, Harigai, M., additional, Hao, Y., additional, Zhang, Z., additional, Basnayake, B., additional, Chan, M., additional, Kikuchi, J., additional, Takeuchi, T., additional, Oon, S., additional, Bae, S. C., additional, O’neill, S., additional, Goldblatt, F., additional, Ng, K., additional, Law, A., additional, Tugnet, N., additional, Kumar, S., additional, Tee, M., additional, Tee, C., additional, Tanaka, Y., additional, Lau, C. S., additional, Nikpour, M., additional, Hoi, A., additional, and Morand, E. F., additional
- Published
- 2023
- Full Text
- View/download PDF
19. Risk Assessment for Breast Cancer Development and Its Clinical Impact on Screening Performance in Iranian Women [Corrigendum]
- Author
-
Nikpour M, Hajian-Tilaki K, and Bakhtiari A
- Subjects
breast cancer risk ,the gail model ,the health belief model ,perceived risk ,the estimated risk ,screening behaviors. ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Nikpour M, Hajian-Tilaki K, Bakhtiari A. Cancer Manag Res. 2019;11:10073–10082. The authors have advised that the acknowledgement statement on page 10081 is incorrect. The text “The research reported in this publication was supported by the Elite Researcher Grant Committee under the award number [958741] from the National Institute for Medical Research Development (NIMAD), Tehran, Iran” should read “The research reported in this publication was supported by the Elite Researcher Grant Committee under the award number [963287] from the National Institute for Medical Research Development (NIMAD), Tehran, Iran”. The authors apologize for this error. Read the original article
- Published
- 2021
20. Association of Modified Systemic Lupus Erythematosus Responder Index Attainment With Long-Term Clinical Outcomes: A Five-Year Prospective Study
- Author
-
Connelly, K, Kandane-Rathnayake, R, Hoi, A, Louthrenoo, W, Hamijoyo, L, Luo, SF, Wu, Y-JJ, Cho, J, Lateef, A, Lau, CS, Chen, Y-H, Navarra, S, Zamora, L, Li, Z, An, Y, Sockalingam, S, Hao, Y, Zhang, Z, Chan, M, Katsumata, Y, Harigai, M, Oon, S, Bae, S-C, O'Neill, S, Gibson, KA, Basnayake, BMDB, Kikuchi, J, Takeuchi, T, Ng, KPL, Tugnet, N, Kumar, S, Goldblatt, F, Law, A, Tee, M, Tee, C, Tanaka, Y, Ohkubo, N, Tan, JY, Karyekar, CS, Nikpour, M, Golder, V, Morand, EF, Connelly, K, Kandane-Rathnayake, R, Hoi, A, Louthrenoo, W, Hamijoyo, L, Luo, SF, Wu, Y-JJ, Cho, J, Lateef, A, Lau, CS, Chen, Y-H, Navarra, S, Zamora, L, Li, Z, An, Y, Sockalingam, S, Hao, Y, Zhang, Z, Chan, M, Katsumata, Y, Harigai, M, Oon, S, Bae, S-C, O'Neill, S, Gibson, KA, Basnayake, BMDB, Kikuchi, J, Takeuchi, T, Ng, KPL, Tugnet, N, Kumar, S, Goldblatt, F, Law, A, Tee, M, Tee, C, Tanaka, Y, Ohkubo, N, Tan, JY, Karyekar, CS, Nikpour, M, Golder, V, and Morand, EF
- Abstract
OBJECTIVE: In trials of systemic lupus erythematosus (SLE), the SLE Responder Index (SRI) is the most commonly used primary efficacy end point but has limited validation against long-term outcomes. We aimed to investigate associations of attainment of a modified version of the SRI (mSRI) with key clinical outcomes in SLE patients with up to 5 years of follow-up. METHODS: We used data from a large multicenter, longitudinal SLE cohort in which patients received standard of care. The first visit with active disease (defined as SLE Disease Activity Index 2000 [SLEDAI-2K] score ≥6) was designated as baseline, and mSRI attainment (defined as a reduction in SLEDAI-2K ≥4 points with no worsening in physician global assessment ≥0.3 points) was determined at annual intervals from baseline up to 5 years. Associations between mSRI attainment and outcomes including disease activity, glucocorticoid dose, flare, damage accrual, Lupus Low Disease Activity State (LLDAS), and remission were studied. RESULTS: We included 2,060 patients, with a median baseline SLEDAI-2K score of 8. An mSRI response was attained by 56% of patients at 1 year, with similar responder rates seen at subsequent annual time points. Compared to nonresponders, mSRI responders had significantly lower disease activity and prednisolone dose and higher proportions of LLDAS and remission attainment at each year, and less damage accrual at years 2 and 3. Furthermore, mSRI responder status at 1 year predicted clinical benefit at subsequent years across most outcomes, including damage accrual (odds ratio [OR] range 0.58-0.69, P < 0.05 for damage accrual ORs at all time points). CONCLUSION: In SLE patients with active disease receiving standard of care, mSRI attainment predicts favorable outcomes over long-term follow-up, supporting the clinical meaningfulness of SRI attainment as an SLE trial end point.
- Published
- 2023
21. How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice
- Author
-
Fairley, JL, Nikpour, M, Mack, HG, Brosnan, M, Saracino, AM, Pellegrini, M, Wicks, IP, Fairley, JL, Nikpour, M, Mack, HG, Brosnan, M, Saracino, AM, Pellegrini, M, and Wicks, IP
- Abstract
Hydroxychloroquine (HCQ) and its close relative chloroquine (CQ) were initially used as antimalarial agents but are now widely prescribed in rheumatology, dermatology and immunology for the management of autoimmune diseases. HCQ is considered to have a better long-term safety profile than CQ and is therefore more commonly used. HCQ has a key role in the treatment of connective tissue diseases including systemic lupus erythematosus (SLE), where it provides beneficial immunomodulation without clinically significant immunosuppression. HCQ can also assist in managing inflammatory arthritis, including rheumatoid arthritis (RA). Debate around toxicity of HCQ in COVID-19 has challenged those who regularly prescribe HCQ to discuss its potential toxicities. Accordingly, we have reviewed the adverse effect profile of HCQ to provide guidance about this therapeutic agent in clinical practice.
- Published
- 2023
22. The emerging association between bronchiectasis and systemic sclerosis: assessing prevalence and potential causality
- Author
-
Smith, R, Harrison, M, Lam, K-V, Adler, B, Bulsara, M, Sahhar, J, Stevens, W, Proudman, S, Nikpour, M, Gabbay, E, Smith, R, Harrison, M, Lam, K-V, Adler, B, Bulsara, M, Sahhar, J, Stevens, W, Proudman, S, Nikpour, M, and Gabbay, E
- Abstract
BACKGROUND: Bronchiectasis has been observed in association with systemic sclerosis (SSc). Theorised aetiology includes aspiration related to oesophageal dysmotility, immunosuppressant medication use and the direct effect of collagen deposition on airway calibre. AIMS: To detail bronchiectasis prevalence in an SSc population who have had a high-resolution computed tomography (HRCT) of the thorax. We assessed whether oesophageal dysmotility, demographic variables, SSc duration or subclass were associated with bronchiectasis. METHODS: Participants in the Australian Scleroderma Cohort Study (ASCS) with a HRCT were included. The ASCS provided demographic and clinical data. HRCT studies were reviewed for bronchiectasis, oesophageal dilatation and interstitial lung disease (ILD). Traction bronchiectasis associated with ILD was recorded as a separate entity to bronchiectasis. Oesophageal dysmotility was defined by symptoms and/or oesophageal dilatation. RESULTS: Of the 256 participants, 16.4% (n = 42) had bronchiectasis. Logistic regression analysis revealed no significant association between bronchiectasis and oesophageal dysmotility (observed in 95.7%), any demographic variable, SSc duration or subclass. A negative association between bronchiectasis and ILD was observed (P = 0.009; odds ratio 0.322; 95% confidence intervals 0.137-0.756). CONCLUSION: Those with SSc appear to have an increased risk for bronchiectasis. Since bronchiectasis was not more frequent in participants with a longer duration of SSc, we hypothesise that its development is not related to immunosuppression alone. Oesophageal dysmotility was almost universal in our population such that its effect on bronchiectasis development could not be concluded. A negative association between bronchiectasis and ILD reflects that bronchiectasis occurring alongside ILD was recorded as a separate entity.
- Published
- 2023
23. Disease specific determinants of cardiopulmonary fitness in systemic sclerosis
- Author
-
Ross, L, Costello, B, Lindqvist, A, Hansen, D, Brown, Z, Stevens, W, Burns, A, Prior, D, Pianta, M, Perera, W, La Gerche, A, Nikpour, M, Ross, L, Costello, B, Lindqvist, A, Hansen, D, Brown, Z, Stevens, W, Burns, A, Prior, D, Pianta, M, Perera, W, La Gerche, A, and Nikpour, M
- Abstract
OBJECTIVES: We aimed to quantify the burden of exercise intolerance in systemic sclerosis (SSc) and explore the disease features that contribute to impaired exercise capacity (measured as peak oxygen uptake, peak VO2) to provide novel mechanistic insights into the causes of physical disability in SSc. METHODS: Thirty-three SSc patients with no history of cardiac disease and no active myositis underwent cardiac and skeletal muscle MRI, transthoracic echocardiography, pulmonary function tests and cardiopulmonary exercise testing (CPET). CPET results were compared to an age-, sex-, and weight-matched controls with no overt cardiopulmonary disease. Native T1 and T2-mapping sequences were used to quantify diffuse fibroinflammatory myocardial disease and qualitative assessment of skeletal muscle oedema was performed. The associations between parameters of cardiorespiratory function and skeletal muscle abnormalities and peak VO2 were evaluated with linear regression analysis. RESULTS: Exercise capacity was markedly impaired in SSc and significantly reduced when compared to control subjects (percent predicted peak VO2: 70% vs 98%, p < 0⋅01). Diffuse myocardial fibroinflammatory disease (p < 0⋅01) and skeletal muscle oedema (p = 0⋅01) were significantly associated with reduced exercise capacity. There was no association between impaired exercise capacity and left ventricular ejection fraction. CONCLUSION: SSc is associated with marked functional impairment that is not explained by commonly used parameters of cardiac function such as left ventricular ejection fraction. Rather, only more sensitive measures of organ involvement are associated with impaired exercise tolerance. Our results show diffuse interstitial changes of the myocardium and skeletal muscle affect oxygen uptake and are important contributors to functional limitation in SSc.
- Published
- 2023
24. Clinical characteristics and survival of pulmonary arterial hypertension with or without interstitial lung disease in systemic sclerosis
- Author
-
Fairley, JL, Hansen, D, Ross, L, Proudman, S, Sahhar, J, Ngian, G-S, Walker, J, Host, L, Morrisroe, K, Apostolopoulous, D, Ferdowsi, N, Wilson, M, Tabesh, M, Stevens, W, Nikpour, M, Fairley, JL, Hansen, D, Ross, L, Proudman, S, Sahhar, J, Ngian, G-S, Walker, J, Host, L, Morrisroe, K, Apostolopoulous, D, Ferdowsi, N, Wilson, M, Tabesh, M, Stevens, W, and Nikpour, M
- Abstract
OBJECTIVES: To describe the clinical phenotype and prognosis of people in the Australian Scleroderma (SSc) Cohort Study with pulmonary arterial hypertension (PAH) with or without interstitial lung disease (ILD). METHODS: Participants meeting ACR/EULAR criteria for SSc were divided into four mutually exclusive groups: those meeting criteria for PAH (PAH-only), ILD (ILD-only), concurrent PAH and ILD (PAH-ILD) or neither PAH nor ILD (SSc-only). Logistic or linear regression analyses were used for associations between clinical features, health-related quality of life (HRQoL) and physical function. Survival analysis was performed using Kaplan-Meier estimates and Cox-regression modelling. RESULTS: Of 1561 participants, 7% fulfilled criteria for PAH-only, 24% ILD-only, 7% PAH-ILD and 62% SSc-only. People with PAH-ILD were more frequently male, with diffuse skin involvement, higher inflammatory markers, older age of SSc onset and higher frequency of extensive ILD than the cohort overall (p < 0.001). People of Asian race more frequently developed PAH-ILD (p < 0.001). People with PAH-ILD or PAH-only had worse WHO functional class and 6-min-walk-distance than ILD-only (p < 0.001). HRQoL scores were worst in those with PAH-ILD (p < 0.001). Survival was reduced in the PAH-only and PAH-ILD groups (p < 0.01). Multivariable hazard modelling demonstrated the worst prognosis in extensive ILD and PAH (HR = 5.65 95% CI 3.50-9.12 p < 0.01), followed by PAH-only (HR = 4.21 95% CI 2.89-6.13 p < 0.01) and PAH with limited ILD (HR = 2.46 95% CI 1.52-3.99 p < 0.01). CONCLUSIONS: The prevalence of concurrent PAH-ILD in the ASCS is 7%, with poorer survival in those patients with PAH-ILD compared to ILD or SSc alone. The presence of PAH confers a poorer overall prognosis than even extensive ILD; however, further data are required to better understand the clinical outcomes of this high-risk patient group.
- Published
- 2023
25. Computing the reduced rank Wiener filter by IQMD
- Author
-
Hua, Yingbo and Nikpour, M
- Subjects
Artificial Intelligence and Image Processing ,Electrical and Electronic Engineering ,Communications Technologies ,Networking & Telecommunications - Published
- 1999
26. Computing the reduced rank Wiener filter by IQMD
- Author
-
Yingbo Hua and Nikpour, M
- Subjects
Networking & Telecommunications ,Electrical and Electronic Engineering ,Communications Technologies - Published
- 1999
27. Investigating the Effect of Different Proportions of Iwan and Window Area of Adjacent Room on Cooling/Heating Load and Energy Consumption in Central Courtyard Model in Yazd
- Author
-
Kamyab, A., primary, Mahmoodi Zarandi, M., additional, and Nikpour, M., additional
- Published
- 2023
- Full Text
- View/download PDF
28. Investigating DesignBuilder Simulation Software's Validation in Term of Heat Gain through Field Measured Data of Adjacent Rooms of Courtyard House
- Author
-
Tayari, N., primary and Nikpour, M., additional
- Published
- 2023
- Full Text
- View/download PDF
29. Inactivation of Aspergillus flavus spores in a sealed package by cold plasma streamers
- Author
-
Sohbatzadeh, F., Mirzanejhad, S., Shokri, H., and Nikpour, M.
- Published
- 2016
- Full Text
- View/download PDF
30. Analysis of miRNA profile in circulating extracellular vesicles of patients with pulmonary arterial hypertension
- Author
-
Khandagale, A, primary, Corcoran, P, additional, Nikpour, M, additional, Siegbahn, A, additional, and Christersson, C, additional
- Published
- 2022
- Full Text
- View/download PDF
31. POS0121 ASSOCIATION OF LUPUS LOW DISEASE ACTIVITY STATE ATTAINMENT WITH REDUCED ORGAN DAMAGE AND FLARE IN SLE PATIENTS WITH HIGH DISEASE ACTIVITY
- Author
-
Kandane-Rathnayake, R., primary, Golder, V., additional, Louthrenoo, W., additional, Chen, Y. H., additional, Cho, J., additional, Lateef, A., additional, Hamijoyo, L., additional, Luo, S. F., additional, Jan Wu, Y. J., additional, Navarra, S., additional, Zamora, L., additional, Li, Z., additional, An, Y., additional, Sockalingam, S., additional, Katsumata, Y., additional, Harigai, M., additional, Hao, Y., additional, Zhang, Z., additional, Basnayake, B., additional, Chan, M., additional, Kikuchi, J., additional, Takeuchi, T., additional, Bae, S. C., additional, Oon, S., additional, O’neill, S., additional, Goldblatt, F., additional, Gibson, K., additional, Ng, K., additional, Law, A., additional, Tugnet, N., additional, Kumar, S., additional, Tee, C., additional, Tee, M., additional, Tanaka, Y., additional, Lau, C. S., additional, Nikpour, M., additional, Morand, E. F., additional, and Hoi, A., additional
- Published
- 2022
- Full Text
- View/download PDF
32. OP0142 COMPARISON OF ATTAINMENT AND PROTECTIVE EFFECTS OF THE LUPUS LOW DISEASE ACTIVITY STATE IN PATIENTS WITH NEWLY DIAGNOSED VERSUS ESTABLISHED SLE - A MULTICENTRE PROSPECTIVE STUDY
- Author
-
Golder, V., primary, Kandane-Rathnayake, R., additional, Louthrenoo, W., additional, Chen, Y. H., additional, Cho, J., additional, Lateef, A., additional, Hamijoyo, L., additional, Luo, S. F., additional, Jan Wu, Y. J., additional, Navarra, S., additional, Zamora, L., additional, LI, Z., additional, An, Y., additional, Sockalingam, S., additional, Katsumata, Y., additional, Harigai, M., additional, Hao, Y., additional, Zhang, Z., additional, Basnayake, B., additional, Chan, M., additional, Kikuchi, J., additional, Takeuchi, T., additional, Bae, S. C., additional, O’neill, S., additional, Goldblatt, F., additional, Oon, S., additional, Gibson, K., additional, Ng, K., additional, Law, A., additional, Tugnet, N., additional, Kumar, S., additional, Tee, C., additional, Tee, M., additional, Tanaka, Y., additional, Lau, C. S., additional, Nikpour, M., additional, Hoi, A., additional, and Morand, E. F., additional
- Published
- 2022
- Full Text
- View/download PDF
33. Gastric antral vascular ectasia in systemic sclerosis: a study of its epidemiology, disease characteristics and impact on survival.
- Author
-
Morrisroe K., Hansen D., Stevens W., Sahhar J., Ngian G.-S., Hill C., Roddy J., Walker J., Proudman S., Nikpour M., Morrisroe K., Hansen D., Stevens W., Sahhar J., Ngian G.-S., Hill C., Roddy J., Walker J., Proudman S., and Nikpour M.
- Abstract
Background: To describe the epidemiology, determinants and survival impact of gastric antral vascular ectasia (GAVE) in systemic sclerosis (SSc). Method(s): Consecutive SSc patients prospectively enrolled in the Australian Scleroderma Cohort Study (ASCS) were included. Univariable and multivariable logistic regression were used to determine the associations of GAVE with clinical manifestations and serological parameters. Kaplan-Meier (K-M) survival curves were used to estimate survival. Result(s): The prevalence of GAVE in this SSc cohort of 2039 SSc patients was 10.6% (n = 216) over a median follow-up period of 4.3(1.7-8.4) years. SSc patients with a history of GAVE compared with those without a history of GAVE were older at SSc onset [49.5 (40.0-58.2) vs 46.7 (36.0-56.7) years, p = 0.05]; more likely to have diffuse disease subtype (dcSSc) (35.3% vs 24.1%, p < 0.001); be negative for Scl-70, U1RNP and Scl/PM antibody (4.0% vs 16.1%, p < 0.001, 3.5% vs 7.4%, p = 0.041, 0.0% vs 2.0%, p = 0.042; and respectively) and positive for RNAP III antibody (24.9% vs 8.3%, p < 0.001). Those with GAVE had a worse HRQoL (p = 0.002). Independent determinants of GAVE included the presence of RNAP III antibody (OR 3.46, p < 0.001), absence of Scl-70 antibody (OR 0.23, p = 0.001), presence of GIT dysmotility (OR 1.64, p = 0.004), and digital ulcers; pits; or digital amputation (OR 1.59, p = 0.014). Conclusion(s): GAVE is an underestimated and underappreciated SSc manifestation of SSc, which occurs with a relatively high frequency. Identifying an at-risk GAVE phenotype, as presented herein, is of practical importance as screening may prove advantageous given GAVE can be easily diagnosed and treated.Copyright © 2022, The Author(s).
- Published
- 2022
34. 2021 DORIS definition of remission in SLE: Final recommendations from an international task force.
- Author
-
van Vollenhoven R.F., Bertsias G., Doria A., Isenberg D., Morand E., Petri M.A., Pons-Estel B.A., Rahman A., Ugarte-Gil M.F., Voskuyl A., Arnaud L., Bruce I.N., Cervera R., Costedoat-Chalumeau N., Gordon C., Houssiau F.A., Mosca M., Schneider M., Ward M.M., Alarcon G., Aringer M., Askenase A., Bae S.-C., Bootsma H., Boumpas D.T., Brunner H., Clarke A.E., Coney C., Czirjak L., Dorner T., Faria R., Fischer R., Fritsch-Stork R., Inanc M., Jacobsen S., Jayne D., Kuhn A., van Leeuw B., Limper M., Mariette X., Navarra S., Nikpour M., Olesinska M.H., Pons-Estel G., Romero-Diaz J., Rubio B., Schoenfeld Y., Bonfa E., Smolen J., Teng Y.K.O., Tincani A., Tsang-A-Sjoe M., Vasconcelos C., Voss A., Werth V.P., Zakharhova E., Aranow C., van Vollenhoven R.F., Bertsias G., Doria A., Isenberg D., Morand E., Petri M.A., Pons-Estel B.A., Rahman A., Ugarte-Gil M.F., Voskuyl A., Arnaud L., Bruce I.N., Cervera R., Costedoat-Chalumeau N., Gordon C., Houssiau F.A., Mosca M., Schneider M., Ward M.M., Alarcon G., Aringer M., Askenase A., Bae S.-C., Bootsma H., Boumpas D.T., Brunner H., Clarke A.E., Coney C., Czirjak L., Dorner T., Faria R., Fischer R., Fritsch-Stork R., Inanc M., Jacobsen S., Jayne D., Kuhn A., van Leeuw B., Limper M., Mariette X., Navarra S., Nikpour M., Olesinska M.H., Pons-Estel G., Romero-Diaz J., Rubio B., Schoenfeld Y., Bonfa E., Smolen J., Teng Y.K.O., Tincani A., Tsang-A-Sjoe M., Vasconcelos C., Voss A., Werth V.P., Zakharhova E., and Aranow C.
- Abstract
Objective To achieve consensus on a definition of remission in SLE (DORIS). Background Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation. Methods Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on. Results Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator's Global Assessment <0.5 (0-3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. Conclusion The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.Copyright © 2021 BMJ Publishing Group. All rights reserved.
- Published
- 2022
35. Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling.
- Author
-
Barbacki A., Baron M., Wang M., Zhang Y., Stevens W., Sahhar J., Proudman S., Nikpour M., Man A., Barbacki A., Baron M., Wang M., Zhang Y., Stevens W., Sahhar J., Proudman S., Nikpour M., and Man A.
- Abstract
OBJECTIVE: Systemic sclerosis (SSc) is an autoimmune disease characterized by progressive organ damage, which can be measured using the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI). We aimed to identify whether distinct trajectories of damage accrual exist and determine which variables are associated with different trajectory groups. METHOD(S): Incident cases of SSc (<2years) were identified in the Australian Scleroderma Interest Group and Canadian Scleroderma Research Group prospective registries. Group-based trajectory modeling was used to identify SCTC-DI trajectories over the cohort's first 5 annual visits. Baseline variables associated with trajectory membership in a univariate analysis were examined in multivariable models. RESULT(S): 410 patients were included. Three trajectory groups were identified: low (54.6%), medium (36.2%) and high (10.3%) damage. Patients with faster damage accrual had higher baseline SCTC-DI. Older age (OR 1.57, 95% CI 1.18 - 2.10), male sex (OR 2.55, 95% CI 1.10 - 5.88), diffuse disease (OR 6.7, 95% CI 2.57 - 17.48), tendon friction rubs (OR 5.4, 95% CI 1.86 - 15.66), and elevated CRP (OR 1.98, 95% CI 1.49 - 2.63) increased the odds of being in the high damage group versus the reference (low damage), whereas Caucasian ethnicity (OR 0.31, 95% CI 0.12 - 0.75) and anti-centromere antibodies (OR 0.24, 95% CI 0.07 - 0.77) decreased them. CONCLUSION(S): We identified three trajectories of damage accrual in a combined incident SSc cohort. Several characteristics increased the odds of belonging to worse trajectories. These findings may be helpful in recognizing patients in whom early aggressive treatment is necessary.Copyright This article is protected by copyright. All rights reserved.
- Published
- 2022
36. 'Not at target': prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study.
- Author
-
Kandane-Rathnayake R., Louthrenoo W., Hoi A., Luo S.-F., Wu Y.-J.J., Chen Y.-H., Cho J., Lateef A., Hamijoyo L., Navarra S.V., Zamora L., Sockalingam S., An Y., Li Z., Katsumata Y., Harigai M., Hao Y., Zhang Z., Kikuchi J., Takeuchi T., Basnayake B.M.D.B., Chan M., Ng K.P.L., Tugnet N., Kumar S., Oon S., Goldblatt F., O'Neill S., Gibson K.A., Ohkubo N., Tanaka Y., Bae S.-C., Lau C.S., Nikpour M., Golder V., Morand E.F., Kandane-Rathnayake R., Louthrenoo W., Hoi A., Luo S.-F., Wu Y.-J.J., Chen Y.-H., Cho J., Lateef A., Hamijoyo L., Navarra S.V., Zamora L., Sockalingam S., An Y., Li Z., Katsumata Y., Harigai M., Hao Y., Zhang Z., Kikuchi J., Takeuchi T., Basnayake B.M.D.B., Chan M., Ng K.P.L., Tugnet N., Kumar S., Oon S., Goldblatt F., O'Neill S., Gibson K.A., Ohkubo N., Tanaka Y., Bae S.-C., Lau C.S., Nikpour M., Golder V., and Morand E.F.
- Abstract
Background: The unmet need in systemic lupus erythematosus (SLE) with the current standard of care is widely recognised, but few studies have quantified this. The recent definition of treat-to-target endpoints and other thresholds of uncontrolled disease activity provide an opportunity to formally define unmet need in SLE. In this study, we enumerated the prevalence of these states and examined their association with adverse outcomes. Method(s): Data were collected prospectively in a 13-country longitudinal SLE cohort between 2013 and 2019. Unmet need was defined as never attaining lupus low disease activity state (LLDAS), a time-adjusted mean SLEDAI-2K (AMS) > 4, or ever experiencing high disease activity status (HDAS; SLEDAI-2K >=10). Health-related quality of life (HRQoL) was assessed using SF36 (v2) and damage accrual using the SLICC-ACR SLE Damage Index (SDI). Result(s): A total of 3384 SLE patients were followed over 30,313 visits (median [IQR] follow-up 2.4 [0.4, 4.3] years). Eight hundred thirteen patients (24%) never achieved LLDAS. Median AMS was 3.0 [1.4, 4.9]; 34% of patients had AMS > 4. Twenty-five per cent of patients had episodes of HDAS. Each of LLDAS-never, AMS>4, and HDAS-ever was strongly associated with damage accrual, higher glucocorticoid use, and worse HRQoL. Mortality was significantly increased in LLDAS-never (adjusted HR [95% CI] = 4.98 [2.07, 12.0], p<0.001) and HDAS-ever (adjusted hazard ratio (HR) [95% CI] = 5.45 [2.75, 10.8], p<0.001) patients. Conclusion(s): Failure to achieve LLDAS, high average disease activity, and episodes of HDAS were prevalent in SLE and were significantly associated with poor outcomes including organ damage, glucocorticoid exposure, poor quality of life, and mortality.Copyright © 2022, The Author(s).
- Published
- 2022
37. Association of clinic setting with quality indicator performance in systemic lupus erythematosus: a cross-sectional study.
- Author
-
Sreedharan S., Li N., Littlejohn G., Buchanan R., Nikpour M., Morand E., Hoi A., Golder V., Sreedharan S., Li N., Littlejohn G., Buchanan R., Nikpour M., Morand E., Hoi A., and Golder V.
- Abstract
Background: Healthcare quality for systemic lupus erythematosus (SLE) is a modifiable target for improving patient outcomes. We aimed to assess the quality of care processes in different clinic settings, comparing a subspecialty lupus clinic with hospital-based and private general rheumatology clinics. Method(s): Patients with SLE (n = 258) were recruited in 2016 from a subspecialty lupus clinic (n = 147), two hospital general rheumatology clinics (n = 56) and two private rheumatology clinics (n = 55). Data were collected from medical records and patient questionnaires. Quality of care was assessed using 31 validated SLE quality indicators (QI) encompassing diagnostic work-up, disease and comorbidity assessments, drug monitoring, preventative care and reproductive health. Per-QI performance was measured as a percentage of patients that met the QI relative to the number of patients eligible. Per-patient QI performance was calculated as a percentage of QIs met relative to the number of eligible QIs for each patient. Per-QI and per-patient QI performance were compared between the three clinic settings, and multiple regression performed to adjust for sociodemographic, disease and healthcare factors. Result(s): Per-QI performance was generally high across all clinic settings for diagnostic work-up, comorbidity assessment, lupus nephritis, drug monitoring, prednisolone taper, osteoporosis and pregnancy care. Median [IQR] per-patient performance on eligible QIs was higher in the subspeciality lupus clinic (66.7% [57.1-74.1]) than the hospital general rheumatology (52.7% [47.5-58.1]) and private rheumatology (50.0% [42.9-60.9]) clinics (p <0.001) and the difference remained significant after multivariable adjustment. The subspecialty lupus clinic recorded higher per-QI performance for documentation of disease activity, disease damage, cardiovascular risk factor and drug toxicity assessments, pre-immunosuppression hepatitis and tuberculosis screening, new medication counsell
- Published
- 2022
38. Contribution of HLA and KIR Alleles to Systemic Sclerosis Susceptibility and Immunological and Clinical Disease Subtypes.
- Author
-
Hanson A.L., Sahhar J., Ngian G.-S., Roddy J., Walker J., Stevens W., Nikpour M., Assassi S., Proudman S., Mayes M.D., Kenna T.J., Brown M.A., Hanson A.L., Sahhar J., Ngian G.-S., Roddy J., Walker J., Stevens W., Nikpour M., Assassi S., Proudman S., Mayes M.D., Kenna T.J., and Brown M.A.
- Abstract
Systemic sclerosis (SSc) is an autoinflammatory, fibrotic condition of unknown aetiology. The presence of detectable autoantibodies against diverse nuclear antigens, as well as strong HLA associations with disease, suggest autoimmune involvement, however the links between endogenous and exogenous risk factors and SSc pathology remain undetermined. We have conducted a genetic analysis of HLA inheritance in two independent and meta-analysed cohorts of 1,465 SSc cases and 13,273 controls, including stratified association analyses in clinical and autoantibody positive subgroups of disease. Additionally, we have used patient genotypes to impute gene dosages across the KIR locus, encoding paired activating and inhibitory lymphocyte receptors for Class I HLA ligands, to conduct the largest analysis of KIR-HLA epistatic interactions in SSc to date. We confirm previous Class II HLA associations with SSc risk and report a new Class I association with haplotype HLA-B*44:03-HLA-C*16:01 at genome-wide significance (GWS). We further report statistically significant HLA associations with clinical and serological subtypes of disease through direct case-case comparison, and report a new association of HLA-DRB1*15:01, previously shown to bind topoisomerase-1 derived peptides, with anti-topoisomerase (ATA) positive disease. Finally, we identify genetic epistasis between KIRs and HLA class I ligands, suggesting genetic modulation of lymphocyte activation may further contribute to an individual's underlying disease risk. Taken together, these findings support future functional investigation into endogenous immunological and environmental stimuli for disrupted immune tolerance in SSc.Copyright © 2022 Hanson, Sahhar, Ngian, Roddy, Walker, Stevens, Nikpour, Assassi, Proudman, Mayes, Kenna and Brown.
- Published
- 2022
39. Using magnetic resonance imaging to map the hidden burden of muscle involvement in systemic sclerosis
- Author
-
Ross, L, Lindqvist, A, Costello, B, Hansen, D, Brown, Z, Day, JA, Stevens, W, Burns, A, Perera, W, Pianta, M, La Gerche, A, Nikpour, M, Ross, L, Lindqvist, A, Costello, B, Hansen, D, Brown, Z, Day, JA, Stevens, W, Burns, A, Perera, W, Pianta, M, La Gerche, A, and Nikpour, M
- Abstract
BACKGROUND: Skeletal muscle can be directly affected by systemic sclerosis (SSc); however, a significant burden of SSc-associated myopathy is undetected because clinical parameters such as weakness and creatine kinase (CK) are unreliable biomarkers of muscle involvement. This study presents qualitative and quantitative magnetic resonance imaging (MRI) findings that quantify the prevalence of myopathy and evaluate any association between skeletal and cardiac muscle involvement in SSc. METHODS: Thirty-two patients with SSc who fulfilled the 2013 American College of Rheumatology/European League Against Rheumatism classification criteria underwent skeletal muscle MRI in addition to cardiac MRI. Skeletal muscles were independently assessed by two musculoskeletal radiologists for evidence of oedema, fatty infiltration and atrophy. Skeletal muscle T2 mapping times and percentage fat fraction were calculated. Linear regression analysis was used to evaluate the clinical and myocardial associations with skeletal muscle oedema and fatty infiltration. Cardiac MRI was performed using post gadolinium contrast imaging and parametric mapping techniques to assess focal and diffuse myocardial fibrosis. RESULTS: Thirteen participants (40.6%) had MRI evidence of skeletal muscle oedema. Five (15.6%) participants had fatty infiltration. There was no association between skeletal muscle oedema and muscle strength, creatine kinase, inflammatory markers or fibroinflammatory myocardial disease. Patients with skeletal muscle oedema had higher T2-mapping times; there was a significant association between subjective assessments of muscle oedema and T2-mapping time (coef 2.46, p = 0.02) and percentage fat fraction (coef 3.41, p = 0.02). Diffuse myocardial fibrosis was a near-universal finding, and one third of patients had focal myocardial fibrosis. There was no association between skeletal myopathy detected by MRI and burden of myocardial disease. CONCLUSIONS: MRI is a sensitive measure of muscl
- Published
- 2022
40. Gastric antral vascular ectasia in systemic sclerosis: a study of its epidemiology, disease characteristics and impact on survival.
- Author
-
Morrisroe, K, Hansen, D, Stevens, W, Sahhar, J, Ngian, G-S, Hill, C, Roddy, J, Walker, J, Proudman, S, Nikpour, M, Morrisroe, K, Hansen, D, Stevens, W, Sahhar, J, Ngian, G-S, Hill, C, Roddy, J, Walker, J, Proudman, S, and Nikpour, M
- Abstract
BACKGROUND: To describe the epidemiology, determinants and survival impact of gastric antral vascular ectasia (GAVE) in systemic sclerosis (SSc). METHODS: Consecutive SSc patients prospectively enrolled in the Australian Scleroderma Cohort Study (ASCS) were included. Univariable and multivariable logistic regression were used to determine the associations of GAVE with clinical manifestations and serological parameters. Kaplan-Meier (K-M) survival curves were used to estimate survival. RESULTS: The prevalence of GAVE in this SSc cohort of 2039 SSc patients was 10.6% (n = 216) over a median follow-up period of 4.3(1.7-8.4) years. SSc patients with a history of GAVE compared with those without a history of GAVE were older at SSc onset [49.5 (40.0-58.2) vs 46.7 (36.0-56.7) years, p = 0.05]; more likely to have diffuse disease subtype (dcSSc) (35.3% vs 24.1%, p < 0.001); be negative for Scl-70, U1RNP and Scl/PM antibody (4.0% vs 16.1%, p < 0.001, 3.5% vs 7.4%, p = 0.041, 0.0% vs 2.0%, p = 0.042; and respectively) and positive for RNAP III antibody (24.9% vs 8.3%, p < 0.001). Those with GAVE had a worse HRQoL (p = 0.002). Independent determinants of GAVE included the presence of RNAP III antibody (OR 3.46, p < 0.001), absence of Scl-70 antibody (OR 0.23, p = 0.001), presence of GIT dysmotility (OR 1.64, p = 0.004), and digital ulcers; pits; or digital amputation (OR 1.59, p = 0.014). CONCLUSIONS: GAVE is an underestimated and underappreciated SSc manifestation of SSc, which occurs with a relatively high frequency. Identifying an at-risk GAVE phenotype, as presented herein, is of practical importance as screening may prove advantageous given GAVE can be easily diagnosed and treated.
- Published
- 2022
41. 'Not at target': prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study.
- Author
-
Kandane-Rathnayake, R, Louthrenoo, W, Hoi, A, Luo, S-F, Wu, Y-JJ, Chen, Y-H, Cho, J, Lateef, A, Hamijoyo, L, Navarra, SV, Zamora, L, Sockalingam, S, An, Y, Li, Z, Katsumata, Y, Harigai, M, Hao, Y, Zhang, Z, Kikuchi, J, Takeuchi, T, Basnayake, BMDB, Chan, M, Ng, KPL, Tugnet, N, Kumar, S, Oon, S, Goldblatt, F, O'Neill, S, Gibson, KA, Ohkubo, N, Tanaka, Y, Bae, S-C, Lau, CS, Nikpour, M, Golder, V, Morand, EF, Asia-Pacific Lupus Collaboration, Kandane-Rathnayake, R, Louthrenoo, W, Hoi, A, Luo, S-F, Wu, Y-JJ, Chen, Y-H, Cho, J, Lateef, A, Hamijoyo, L, Navarra, SV, Zamora, L, Sockalingam, S, An, Y, Li, Z, Katsumata, Y, Harigai, M, Hao, Y, Zhang, Z, Kikuchi, J, Takeuchi, T, Basnayake, BMDB, Chan, M, Ng, KPL, Tugnet, N, Kumar, S, Oon, S, Goldblatt, F, O'Neill, S, Gibson, KA, Ohkubo, N, Tanaka, Y, Bae, S-C, Lau, CS, Nikpour, M, Golder, V, Morand, EF, and Asia-Pacific Lupus Collaboration
- Abstract
BACKGROUND: The unmet need in systemic lupus erythematosus (SLE) with the current standard of care is widely recognised, but few studies have quantified this. The recent definition of treat-to-target endpoints and other thresholds of uncontrolled disease activity provide an opportunity to formally define unmet need in SLE. In this study, we enumerated the prevalence of these states and examined their association with adverse outcomes. METHODS: Data were collected prospectively in a 13-country longitudinal SLE cohort between 2013 and 2019. Unmet need was defined as never attaining lupus low disease activity state (LLDAS), a time-adjusted mean SLEDAI-2K (AMS) > 4, or ever experiencing high disease activity status (HDAS; SLEDAI-2K ≥10). Health-related quality of life (HRQoL) was assessed using SF36 (v2) and damage accrual using the SLICC-ACR SLE Damage Index (SDI). RESULTS: A total of 3384 SLE patients were followed over 30,313 visits (median [IQR] follow-up 2.4 [0.4, 4.3] years). Eight hundred thirteen patients (24%) never achieved LLDAS. Median AMS was 3.0 [1.4, 4.9]; 34% of patients had AMS > 4. Twenty-five per cent of patients had episodes of HDAS. Each of LLDAS-never, AMS>4, and HDAS-ever was strongly associated with damage accrual, higher glucocorticoid use, and worse HRQoL. Mortality was significantly increased in LLDAS-never (adjusted HR [95% CI] = 4.98 [2.07, 12.0], p<0.001) and HDAS-ever (adjusted hazard ratio (HR) [95% CI] = 5.45 [2.75, 10.8], p<0.001) patients. CONCLUSION: Failure to achieve LLDAS, high average disease activity, and episodes of HDAS were prevalent in SLE and were significantly associated with poor outcomes including organ damage, glucocorticoid exposure, poor quality of life, and mortality.
- Published
- 2022
42. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis
- Author
-
Kerick, M., Acosta-Herrera, M., Simeón-Aznar, C.P., Callejas, J.L., Assassi, S., Proudman, S.M., Nikpour, M., Hunzelmann, N., Moroncini, G., Vries-Bouwstra, J.K. de, Orozco, G., Barton, A., Herrick, A.L., Terao, C., Allanore, Y., Fonseca, C., Alarcón-Riquelme, M.E., Radstake, T.R., Beretta, L., Denton, C.P., Vonk, M.C., Mayes, M.D., Martin, J., Kerick, M., Acosta-Herrera, M., Simeón-Aznar, C.P., Callejas, J.L., Assassi, S., Proudman, S.M., Nikpour, M., Hunzelmann, N., Moroncini, G., Vries-Bouwstra, J.K. de, Orozco, G., Barton, A., Herrick, A.L., Terao, C., Allanore, Y., Fonseca, C., Alarcón-Riquelme, M.E., Radstake, T.R., Beretta, L., Denton, C.P., Vonk, M.C., Mayes, M.D., and Martin, J.
- Abstract
Item does not contain fulltext, Copy number (CN) polymorphisms of complement C4 play distinct roles in many conditions, including immune-mediated diseases. We investigated the association of C4 CN with systemic sclerosis (SSc) risk. Imputed total C4, C4A, C4B, and HERV-K CN were analyzed in 26,633 individuals and validated in an independent cohort. Our results showed that higher C4 CN confers protection to SSc, and deviations from CN parity of C4A and C4B augmented risk. The protection contributed per copy of C4A and C4B differed by sex. Stronger protection was afforded by C4A in men and by C4B in women. C4 CN correlated well with its gene expression and serum protein levels, and less C4 was detected for both in SSc patients. Conditioned analysis suggests that C4 genetics strongly contributes to the SSc association within the major histocompatibility complex locus and highlights classical alleles and amino acid variants of HLA-DRB1 and HLA-DPB1 as C4-independent signals.
- Published
- 2022
43. Association of clinic setting with quality indicator performance in systemic lupus erythematosus: a cross-sectional study
- Author
-
Sreedharan, S, Li, N, Littlejohn, G, Buchanan, R, Nikpour, M, Morand, E, Hoi, A, Golder, V, Sreedharan, S, Li, N, Littlejohn, G, Buchanan, R, Nikpour, M, Morand, E, Hoi, A, and Golder, V
- Abstract
BACKGROUND: Healthcare quality for systemic lupus erythematosus (SLE) is a modifiable target for improving patient outcomes. We aimed to assess the quality of care processes in different clinic settings, comparing a subspecialty lupus clinic with hospital-based and private general rheumatology clinics. METHODS: Patients with SLE (n = 258) were recruited in 2016 from a subspecialty lupus clinic (n = 147), two hospital general rheumatology clinics (n = 56) and two private rheumatology clinics (n = 55). Data were collected from medical records and patient questionnaires. Quality of care was assessed using 31 validated SLE quality indicators (QI) encompassing diagnostic work-up, disease and comorbidity assessments, drug monitoring, preventative care and reproductive health. Per-QI performance was measured as a percentage of patients that met the QI relative to the number of patients eligible. Per-patient QI performance was calculated as a percentage of QIs met relative to the number of eligible QIs for each patient. Per-QI and per-patient QI performance were compared between the three clinic settings, and multiple regression performed to adjust for sociodemographic, disease and healthcare factors. RESULTS: Per-QI performance was generally high across all clinic settings for diagnostic work-up, comorbidity assessment, lupus nephritis, drug monitoring, prednisolone taper, osteoporosis and pregnancy care. Median [IQR] per-patient performance on eligible QIs was higher in the subspeciality lupus clinic (66.7% [57.1-74.1]) than the hospital general rheumatology (52.7% [47.5-58.1]) and private rheumatology (50.0% [42.9-60.9]) clinics (p <0.001) and the difference remained significant after multivariable adjustment. The subspecialty lupus clinic recorded higher per-QI performance for documentation of disease activity, disease damage, cardiovascular risk factor and drug toxicity assessments, pre-immunosuppression hepatitis and tuberculosis screening, new medication counselling
- Published
- 2022
44. Contribution of HLA and KIR Alleles to Systemic Sclerosis Susceptibility and Immunological and Clinical Disease Subtypes
- Author
-
Hanson, AL, Sahhar, J, Ngian, G-S, Roddy, J, Walker, J, Stevens, W, Nikpour, M, Assassi, S, Proudman, S, Mayes, MD, Kenna, TJ, Brown, MA, Hanson, AL, Sahhar, J, Ngian, G-S, Roddy, J, Walker, J, Stevens, W, Nikpour, M, Assassi, S, Proudman, S, Mayes, MD, Kenna, TJ, and Brown, MA
- Abstract
Systemic sclerosis (SSc) is an autoinflammatory, fibrotic condition of unknown aetiology. The presence of detectable autoantibodies against diverse nuclear antigens, as well as strong HLA associations with disease, suggest autoimmune involvement, however the links between endogenous and exogenous risk factors and SSc pathology remain undetermined. We have conducted a genetic analysis of HLA inheritance in two independent and meta-analysed cohorts of 1,465 SSc cases and 13,273 controls, including stratified association analyses in clinical and autoantibody positive subgroups of disease. Additionally, we have used patient genotypes to impute gene dosages across the KIR locus, encoding paired activating and inhibitory lymphocyte receptors for Class I HLA ligands, to conduct the largest analysis of KIR-HLA epistatic interactions in SSc to date. We confirm previous Class II HLA associations with SSc risk and report a new Class I association with haplotype HLA-B*44:03-HLA-C*16:01 at genome-wide significance (GWS). We further report statistically significant HLA associations with clinical and serological subtypes of disease through direct case-case comparison, and report a new association of HLA-DRB1*15:01, previously shown to bind topoisomerase-1 derived peptides, with anti-topoisomerase (ATA) positive disease. Finally, we identify genetic epistasis between KIRs and HLA class I ligands, suggesting genetic modulation of lymphocyte activation may further contribute to an individual's underlying disease risk. Taken together, these findings support future functional investigation into endogenous immunological and environmental stimuli for disrupted immune tolerance in SSc.
- Published
- 2022
45. Myocardial fibrosis and arrhythmic burden in systemic sclerosis
- Author
-
Ross, L, Costello, B, Brown, Z, Hansen, D, Lindqvist, A, Stevens, W, Burns, A, Prior, D, Nikpour, M, La Gerche, A, Ross, L, Costello, B, Brown, Z, Hansen, D, Lindqvist, A, Stevens, W, Burns, A, Prior, D, Nikpour, M, and La Gerche, A
- Abstract
OBJECTIVES: Cardiac complications of SSc are a leading cause of SSc-associated death. Cardiac imaging for identifying substrate abnormality may be useful in predicting risk of cardiac arrhythmias or future cardiac failure. The aim of this study was to quantify the burden of asymptomatic fibro-inflammatory myocardial disease using cardiac magnetic resonance imaging (CMR) and assess the relationship between asymptomatic myocardial fibrosis and cardiac arrhythmias in SSc. METHODS: Thirty-two patients with SSc with no documented history of pulmonary vascular or heart disease underwent CMR with gadolinium and 24-h ambulatory ECG. Focal myocardial fibrosis was assessed using post-gadolinium imaging and diffuse fibro-inflammatory myocardial disease quantified using T1- and T2-mapping. CMR results were compared with an age- and sex-matched control group. RESULTS: Post-gadolinium focal fibrosis was prevalent in SSc but not controls (30% vs 0%, p < 0.01).. T1-mapping values (as a marker of diffuse fibrosis) were greater in SSc than controls [saturated recovery single-shot acquisition (SASHA): 1584 ms vs 1515 ms, P < 0.001; shortened Modified look locker sequence (ShMOLLI): 1218 ms vs 1138 ms, p < 0.001]. More than one-fifth (22.6%) of the participants had ventricular arrhythmias on ambulatory ECG, but no associations between focal or diffuse myocardial fibrosis and arrhythmias were evident. CONCLUSION: In SSc patients without evidence of overt cardiac disease, a high burden of myocardial fibrosis and arrhythmias was identified. However, there was no clear association between focal or diffuse myocardial fibrosis and arrhythmias, suggesting CMR may have limited use as a screening tool to identify SSc patients at risk of future significant arrhythmias.
- Published
- 2022
46. The Effect of Body Fat Distribution on Systemic Sclerosis
- Author
-
Villanueva-Martin, G, Acosta-Herrera, M, Kerick, M, Lopez-Isac, E, Simeon, CP, Callejas, JL, Assassi, S, Beretta, L, Allanore, Y, Proudman, SM, Nikpour, M, Fonseca, C, Denton, CP, Radstake, TRDJ, Mayes, MD, Jiang, X, Martin, J, Bossini-Castillo, L, Villanueva-Martin, G, Acosta-Herrera, M, Kerick, M, Lopez-Isac, E, Simeon, CP, Callejas, JL, Assassi, S, Beretta, L, Allanore, Y, Proudman, SM, Nikpour, M, Fonseca, C, Denton, CP, Radstake, TRDJ, Mayes, MD, Jiang, X, Martin, J, and Bossini-Castillo, L
- Abstract
Obesity contributes to a chronic proinflammatory state, which is a known risk factor to develop immune-mediated diseases. However, its role in systemic sclerosis (SSc) remains to be elucidated. Therefore, we conducted a two-sample mendelian randomization (2SMR) study to analyze the effect of three body fat distribution parameters in SSc. As instrumental variables, we used the allele effects described for single nucleotide polymorphisms (SNPs) in different genome-wide association studies (GWAS) for SSc, body mass index (BMI), waist-to-hip ratio (WHR) and WHR adjusted for BMI (WHRadjBMI). We performed local (pHESS) and genome-wide (LDSC) genetic correlation analyses between each of the traits and SSc and we applied several Mendelian randomization (MR) methods (i.e., random effects inverse-variance weight, MR-Egger regression, MR pleiotropy residual sum and outlier method and a multivariable model). Our results show no genetic correlation or causal relationship between any of these traits and SSc. Nevertheless, we observed a negative causal association between WHRadjBMI and SSc, which might be due to the effect of gastrointestinal complications suffered by the majority of SSc patients. In conclusion, reverse causality might be an especially difficult confounding factor to define the effect of obesity in the onset of SSc.
- Published
- 2022
47. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis
- Author
-
Kerick, M, Acosta-Herrera, M, Pilar Simeon-Aznar, C, Luis Callejas, J, Assassi, S, Proudman, SM, Nikpour, M, Hunzelmann, N, Moroncini, G, de Vries-Bouwstra, JK, Orozco, G, Barton, A, Herrick, AL, Terao, C, Allanore, Y, Fonseca, C, Eugenia Alarcon-Riquelme, M, Radstake, TRDJ, Beretta, L, Denton, CP, Mayes, MD, Martin, J, Kerick, M, Acosta-Herrera, M, Pilar Simeon-Aznar, C, Luis Callejas, J, Assassi, S, Proudman, SM, Nikpour, M, Hunzelmann, N, Moroncini, G, de Vries-Bouwstra, JK, Orozco, G, Barton, A, Herrick, AL, Terao, C, Allanore, Y, Fonseca, C, Eugenia Alarcon-Riquelme, M, Radstake, TRDJ, Beretta, L, Denton, CP, Mayes, MD, and Martin, J
- Abstract
Copy number (CN) polymorphisms of complement C4 play distinct roles in many conditions, including immune-mediated diseases. We investigated the association of C4 CN with systemic sclerosis (SSc) risk. Imputed total C4, C4A, C4B, and HERV-K CN were analyzed in 26,633 individuals and validated in an independent cohort. Our results showed that higher C4 CN confers protection to SSc, and deviations from CN parity of C4A and C4B augmented risk. The protection contributed per copy of C4A and C4B differed by sex. Stronger protection was afforded by C4A in men and by C4B in women. C4 CN correlated well with its gene expression and serum protein levels, and less C4 was detected for both in SSc patients. Conditioned analysis suggests that C4 genetics strongly contributes to the SSc association within the major histocompatibility complex locus and highlights classical alleles and amino acid variants of HLA-DRB1 and HLA-DPB1 as C4-independent signals.
- Published
- 2022
48. Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling
- Author
-
Barbacki, A, Baron, M, Wang, M, Zhang, Y, Stevens, W, Sahhar, J, Proudman, S, Nikpour, M, Man, A, Barbacki, A, Baron, M, Wang, M, Zhang, Y, Stevens, W, Sahhar, J, Proudman, S, Nikpour, M, and Man, A
- Abstract
OBJECTIVE: Systemic sclerosis (SSc) is an autoimmune disease characterized by progressive organ damage, which can be measured using the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI). We aimed to identify whether distinct trajectories of damage accrual exist and to determine which variables are associated with different trajectory groups. METHODS: Incident cases of SSc (<2 years) were identified in the Australian Scleroderma Interest Group and Canadian Scleroderma Research Group prospective registries. Group-based trajectory modeling was used to identify SCTC-DI trajectories over the cohort's first 5 annual visits. Baseline variables associated with trajectory membership in a univariate analysis were examined in multivariable models. RESULTS: A total of 410 patients were included. Three trajectory groups were identified: low (54.6%), medium (36.2%), and high (10.3%) damage. Patients with faster damage accrual had higher baseline SCTC-DI scores. Older age (odds ratio [OR] 1.57 [95% confidence interval (95% CI) 1.18-2.10]), male sex (OR 2.55 [95% CI 1.10-5.88]), diffuse disease (OR 6.7 [95% CI 2.57-17.48]), tendon friction rubs (OR 5.4 [95% CI 1.86-15.66]), and elevated C-reactive protein level (OR 1.98 [95% CI 1.49-2.63]) increased the odds of being in the high-damage group versus the reference (low damage), whereas White ethnicity (OR 0.31 [95% CI 0.12-0.75]) and anticentromere antibodies (OR 0.24 [95% CI 0.07-0.77]) decreased the odds. CONCLUSION: We identified 3 trajectories of damage accrual in a combined incident SSc cohort. Several characteristics increased the odds of belonging to worse trajectories. These findings may be helpful in recognizing patients in whom early aggressive treatment is necessary.
- Published
- 2022
49. The effect of body fat distribution on systemic sclerosis.
- Author
-
Villanueva-Martín, Gonzalo, Acosta-Herrera, Marialbert, Kerick, Martin, López-Isac, Elena, Simeón, Carmen P., Callejas, Jose Luis, Assassi, S., Beretta, Lorenzo, Allanore, Yannick, Proudman, Susan, Nikpour, M, Fonseca, Carmen, Denton, Christopher, Radstake, Timothy R. D. J., Mayes, Maureen D., Jiang, Xia, Martin, Javier, Bossini-Castillo, Lara, Villanueva-Martín, Gonzalo, Acosta-Herrera, Marialbert, Kerick, Martin, López-Isac, Elena, Simeón, Carmen P., Callejas, Jose Luis, Assassi, S., Beretta, Lorenzo, Allanore, Yannick, Proudman, Susan, Nikpour, M, Fonseca, Carmen, Denton, Christopher, Radstake, Timothy R. D. J., Mayes, Maureen D., Jiang, Xia, Martin, Javier, and Bossini-Castillo, Lara
- Published
- 2022
50. Associations between pre-operative radiographic changes and outcomes after total knee joint replacement for osteoarthritis
- Author
-
Dowsey, M.M., Nikpour, M., Dieppe, P., and Choong, P.F.M.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.